Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group.
The estrogen decrease of the postmenopausal state may be a factor in both the pathogenesis of late-life depression and in therapeutic response. Studies of nondepressed women over 60 given estrogen replacement therapy (ERT) suggest improvement in mood. The authors compared clinical response of elderly depressed women outpatients entering a 6-week, randomized, placebo-controlled, double-blind, multicenter trial of fluoxetine (20 mg/day); 72 patients received ERT, and 286 did not. There was a significant interaction between ERT status and treatment effect (P = 0.015). Patients on ERT who received fluoxetine had substantially greater mean Ham-D percentage improvement than patients on ERT who received placebo (40.1% vs. 17.0%, respectively); fluoxetine-treated patients not on ERT did not show benefit significantly greater than placebo-treated patients not on ERT. ERT use may augment fluoxetine response in elderly depressed outpatients and should be considered as a factor in clinical trials in elderly women.
Schneider
L S
LS
Department of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, USA.
Small
G W
GW
Hamilton
S H
SH
Bystritsky
A
A
Nemeroff
C B
CB
Meyers
B S
BS
D000339:Affect; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D016014:Linear Models; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index
D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine